Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

ConditionBeta Blocker Toxicity

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age50+

SponsorSherief Abd-Elsalam

About this trial

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

• Male & female osteoporotic patient aged ≥ 50 years

Hypertensive & normotensive patients

BMD T-score ≥ 2.5 or more SD below peak bone mass

Disqualifiers

Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.

Trial design

Design model

Parallel

Treatments tested in this trial

nonselective beta blocker
Drug
nonselective beta blocker
cardio-selective beta blocker group
Drug
cardio-selective beta blocker group
alendronate sodium
Drug
alendronate sodium

Treatment groups

50 Participants

are divided into 3 treatment groups

Group A: nonselective beta blocker groupExperimental treatment 2 interventions

Group B: cardio-selective beta blocker groupExperimental treatment 2 interventions

Group C: Control groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Number of patients with fracture in each group

the exact number of patients with fracture in each group

Time frame

1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sherief Abd-Elsalam

Lead sponsor

Tanta University

Sponsor institution

Source ClinicalTrials.gov

Apply now